We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+12.76%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$478M
AUM Growth
+$56.7M
Cap. Flow
+$17.4M
Cap. Flow %
3.64%
Top 10 Hldgs %
53.49%
Holding
96
New
7
Increased
25
Reduced
16
Closed
12

Top Buys

Rank Stock Value
1
TBPH icon
Theravance Biopharma
TBPH
+$13M
2
FSTX
F-star Therapeutics, Inc. Common Stock
FSTX
+$6.09M
3
OTIC
Otonomy, Inc.
OTIC
+$4.6M
4
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$2.98M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$2.8M

Top Sells

Rank Stock Value
1
PLX icon
Protalix BioTherapeutics
PLX
+$5.37M
2
ATRC icon
AtriCure
ATRC
+$2.69M
3
ALEC icon
Alector
ALEC
+$2.57M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$2.36M
5
AGTC
Applied Genetic Technologies Corporation
AGTC
+$2.18M

Sector Composition

Rank Sector Weight
1 Healthcare 97.51%
2 Miscellaneous 2.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STXS icon
1
Stereotaxis
STXS
$145M
$132M 27.58%
13,680,554
– –
FATE icon
2
Fate Therapeutics
FATE
$291M
$27.3M 5.71%
314,360
– –
DRNA
3
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$19.1M 3.99%
510,756
-77,000
-13% -$2.36M
BPMC
4
DELISTED
Blueprint Medicines
BPMC
$18.3M 3.82%
207,911
– –
TBPH icon
5
Theravance Biopharma
TBPH
$885M
$10.6M 2.22%
732,345
+691,180
+1,679% +$13M
MORF
6
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$10.4M 2.18%
181,467
– –
TBIO
7
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$10.4M 2.17%
376,993
+151,600
+67% +$2.98M
SAGE
8
DELISTED
Sage Therapeutics
SAGE
$9.68M 2.02%
170,306
-11,000
-6% -$778K
BHVN
9
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$9.13M 1.91%
94,100
+500
+0.5% +$40.6K
DXCM icon
10
DexCom
DXCM
$34.3B
$9.03M 1.89%
84,552
– –
AFMD
11
DELISTED
Affimed
AFMD
$8.2M 1.72%
96,486
-2,500
-3% -$228K
ARNA
12
DELISTED
Arena Pharmaceuticals Inc
ARNA
$8.16M 1.71%
119,615
+42,900
+56% +$2.8M
NRIX icon
13
Nurix Therapeutics
NRIX
$2.72B
$8.13M 1.7%
306,320
– –
XENE icon
14
Xenon Pharmaceuticals
XENE
$5.81B
$7.57M 1.58%
406,535
– –
ATRC icon
15
AtriCure
ATRC
$2.47B
$7.26M 1.52%
91,529
-37,000
-29% -$2.69M
NBIX icon
16
Neurocrine Biosciences
NBIX
$15.7B
$7.17M 1.5%
73,655
– –
IDYA icon
17
IDEAYA Biosciences
IDYA
$3.87B
$6.96M 1.46%
331,661
– –
PRQR icon
18
ProQR Therapeutics
PRQR
$323M
$6.96M 1.45%
1,031,880
-68,120
-6% -$439K
IBB icon
19
iShares Biotechnology ETF
IBB
$10.5B
$6.69M 1.4%
40,900
+500
+1% +$77K
RVMD icon
20
Revolution Medicines
RVMD
$44.6B
$6.66M 1.39%
209,731
+58,500
+39% +$2.04M
CSII
21
DELISTED
Cardiovascular Systems, Inc.
CSII
$6.38M 1.34%
149,700
– –
FSTX
22
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$6.14M 1.28%
+714,285
New +$6.09M
KRTX
23
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$6.04M 1.26%
53,000
+5,000
+10% +$584K
LKFT
24
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$5.35M 1.12%
77,675
+2,500
+3% +$191K
OTIC
25
DELISTED
Otonomy, Inc.
OTIC
$5.31M 1.11%
2,379,392
+1,989,800
+511% +$4.6M
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, DAFNA Capital Management held 96 positions worth $478M, up 13% from $421M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

DAFNA Capital Management deployed $17.4M of net new capital in Q2 2021, opening 7 new positions and adding to 25 existing holdings. Its largest new stake was F-star Therapeutics, Inc. Common Stock: 714,285 shares worth $6.14M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was AtriCure, an estimated $2.69M trimmed.

  • DAFNA Capital Management's largest Q2 2021 buy was F-star Therapeutics, Inc. Common Stock: 714,285 shares worth $6.14M.
  • DAFNA Capital Management added most to Theravance Biopharma in Q2 2021, an estimated $13M increase.
  • DAFNA Capital Management's biggest Q2 2021 reduction was AtriCure, cutting an estimated $2.69M.
  • DAFNA Capital Management fully exited Protalix BioTherapeutics in Q2 2021, selling an estimated $5.37M.
  • DAFNA Capital Management's ten largest holdings make up 53% of its $478M portfolio in Q2 2021.
  • DAFNA Capital Management opened 7 new positions and closed 12 in Q2 2021.
  • DAFNA Capital Management's portfolio value rose 13% quarter-over-quarter to $478M.

Based on DAFNA Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.